United Therapeutics Corp. SEC Filings

United Therapeutics (UTHR) filed a Form 4 disclosing that EVP & General Counsel Paul A. Mahon exercised 11,000 stock options at $135.42 and immediately sold the same 11,000 shares on 26 Jun 2025 at weighted-average prices between $283.52 and $288.80, generating gross proceeds of roughly $3.1 million.

The sale, executed under a pre-arranged 10b5-1 plan adopted 24 Dec 2024, reduced Mahon’s direct holdings by about 23 % to 36,781 shares; he still holds 121,000 options. No other executives were involved.

This sizable insider disposition may influence investor sentiment even though it was pre-planned.

United Therapeutics (Nasdaq: UTHR) filed an 8-K covering its June 26 2025 annual meeting. Shareholders re-elected all 13 directors, approved the non-binding say-on-pay vote, and ratified Ernst & Young as auditor. The meeting also approved an amendment and restatement of the 2015 Stock Incentive Plan, adding 950,000 shares, extending the plan to April 24 2035, and increasing the Lead Independent Director retainer by $5,000. No other material financial or operational changes were disclosed.

United Therapeutics Corp. (UTHR) – Form 144 filing summary

Officer Paul A. Mahon has filed a Form 144 indicating his intent to sell 11,000 common shares of United Therapeutics on or after 26 Jun 2025 through Morgan Stanley Smith Barney. The shares have an estimated aggregate market value of $3.14 million. The company has 45.11 million shares outstanding, so the proposed sale represents roughly 0.024 % of shares outstanding.

Recent insider activity:

• During the past three months, Mahon has already sold 66,000 shares across seven transactions, generating $19.60 million in gross proceeds.
• If the newly-noticed 11,000-share tranche is executed, cumulative sales since 3 Apr 2025 will reach 77,000 shares (≈ 0.17 % of outstanding).

The filing cites a 10b5-1 trading plan adopted on 24 Dec 2024, and the signer affirms no undisclosed material adverse information. No other financial data or corporate developments are disclosed in this notice.

Key takeaways for investors:

• Continued insider selling by a senior officer may be interpreted as a modestly negative sentiment signal, though the percentage of total shares is small.
• The existence of a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading.
• No operational, earnings, or strategic information is included; the filing is strictly a regulatory notice of planned sales.

United Therapeutics Corporation (UTHR) – Form 4 insider transaction

Director Nilda Mesa reported the sale of 645 common shares on 24-Jun-2025 at a weighted-average price of $289.99 (actual trade range: $289.68-$290.05). Following the sale, Mesa’s direct holdings declined to 4,883 shares. No derivative securities were involved and no 10b5-1 trading plan was indicated.

The filing was signed under power of attorney on 25-Jun-2025. No other transactions, options, or changes in indirect ownership were disclosed.

United Therapeutics Corp (UTHR) – Form 144 filing: An insider has notified the SEC of a planned sale of 645 common shares through Morgan Stanley Smith Barney on or about 24 June 2025. The shares were originally received as restricted stock on 13 July 2024 directly from the issuer. The proposed transaction has an aggregate market value of $187,045.23, representing roughly 0.001 % of the company’s 45,106,623 shares outstanding. No prior sales were reported in the past three months. Because the volume is extremely small relative to the float and there are no accompanying disclosures of adverse information, the filing appears routine and is unlikely to affect United Therapeutics’ capital structure or trading liquidity.

United Therapeutics Corp. (UTHR) has filed a Form 144, indicating the intent of an insider to sell up to 3,036 common shares through Morgan Stanley Smith Barney on or after 24 June 2025. At the most recent reference price the shares carry an aggregate market value of $879,214. The shares represent roughly 0.007 % of the company’s 45.1 million shares outstanding, making the proposed sale immaterial to the capital structure.

The shares were acquired the same day via stock-option exercise, suggesting the filer is a company insider monetising a portion of vested options. No prior sales were reported in the past three months, and the filer attests to having no undisclosed adverse information about the company. A Form 144 filing is a notice of intent—not a guarantee—that the sale will occur; actual execution will be disclosed, if completed, on a subsequent Form 4.

For investors, the filing merely signals a routine, small-scale insider liquidity event and does not, by itself, imply any change in the underlying fundamentals or outlook for UTHR.